Your browser is no longer supported. Please, upgrade your browser.
Settings
ADAP Adaptimmune Therapeutics plc daily Stock Chart
ADAP [NASD]
Adaptimmune Therapeutics plc
Index- P/E- EPS (ttm)-0.93 Insider Own0.25% Shs Outstand112.69M Perf Week-12.14%
Market Cap611.91M Forward P/E- EPS next Y-1.18 Insider Trans- Shs Float11.25M Perf Month-50.09%
Income-86.60M PEG- EPS next Q-0.33 Inst Own63.00% Short Float30.49% Perf Quarter-34.34%
Sales62.30M P/S9.82 EPS this Y21.10% Inst Trans15.61% Short Ratio6.14 Perf Half Y-55.46%
Book/sh2.85 P/B1.91 EPS next Y-22.90% ROA-33.00% Target Price15.88 Perf Year-32.29%
Cash/sh2.11 P/C2.57 EPS next 5Y13.50% ROE-41.50% 52W Range5.35 - 14.63 Perf YTD-18.71%
Dividend- P/FCF- EPS past 5Y-58.90% ROI-40.00% 52W High-62.87% Beta2.02
Dividend %- Quick Ratio8.80 Sales past 5Y- Gross Margin- 52W Low1.50% ATR0.74
Employees371 Current Ratio8.80 Sales Q/Q50.00% Oper. Margin- RSI (14)25.35 Volatility8.78% 11.59%
OptionableYes Debt/Eq0.00 EPS Q/Q640.40% Profit Margin- Rel Volume1.11 Prev Close5.50
ShortableYes LT Debt/Eq0.00 EarningsNov 06 BMO Payout- Avg Volume558.93K Price5.43
Recom2.10 SMA20-18.53% SMA50-45.66% SMA200-48.89% Volume618,043 Change-1.27%
Mar-17-17Initiated Wells Fargo Market Perform
Oct-24-16Downgrade BofA/Merrill Neutral → Underperform
Sep-30-16Initiated Raymond James Outperform $16
Feb-25-16Initiated Citigroup Buy $15
Jun-01-15Initiated Leerink Partners Outperform $24
Jun-01-15Initiated Guggenheim Buy
Jun-01-15Initiated BofA/Merrill Neutral
Nov-14-18 11:10AM  What You Must Know About Adaptimmune Therapeutics plcs (NASDAQ:ADAP) Financial Strength Simply Wall St. -5.83%
Nov-07-18 03:30PM  Edited Transcript of ADAP earnings conference call or presentation 6-Nov-18 1:00pm GMT Thomson Reuters StreetEvents
Nov-06-18 07:30AM  Adaptimmune Reports Third Quarter 2018 Financial Results and Business Update GlobeNewswire -8.42%
Oct-25-18 04:30PM  Adaptimmune to Report Third Quarter 2018 Financial Results and Business Update on Tuesday, November 6, 2018 GlobeNewswire
08:53AM  3 Beaten-Down Biotech Stocks: Can They Bounce Back? Motley Fool
07:29AM  Adaptimmune Therapeutics Worldwide Enters Oversold Territory Zacks
Oct-22-18 09:48AM  Adaptimmune's stock tumbles after cancer study results prompts price target cut MarketWatch -29.83%
Oct-20-18 10:45AM  Updated Data from Ongoing MAGE-A10 and MAGE-A4 Studies Presented at the 2018 ESMO Congress GlobeNewswire
Oct-17-18 07:20AM  Investor Expectations to Drive Momentum within Arsanis, Dynavax Technologies, Puma Biotechnology, Opko Health, Adaptimmune Therapeutics, and Codexis Discovering Underlying Factors of Influence GlobeNewswire
Oct-08-18 06:10PM  Data Updates from Ongoing MAGE-A10 Studies and MAGE-A4 Study to be presented at the European Society for Medical Oncology (ESMO) 2018 Congress GlobeNewswire -5.04%
Sep-19-18 07:30AM  3 Biotech Stocks That Big Investors Are Snatching Up Barrons.com
Sep-13-18 09:19AM  Should You Be Holding Adaptimmune Therapeutics plc (NASDAQ:ADAP) Right Now? Simply Wall St.
Sep-07-18 01:14PM  Adaptimmune Therapeutics plc Announces Closing of Registered Direct Offering of American Depositary Shares GlobeNewswire
Sep-05-18 07:30AM  Adaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary Shares GlobeNewswire
Aug-24-18 10:37AM  Options Traders Expect Huge Moves in Adaptimmune (ADAP) Stock Zacks +11.05%
Aug-20-18 08:30AM  Investor Expectations to Drive Momentum within NEXEO SOLUTIONS, Altisource Portfolio Solutions S.A, Celestica, Star Bulk Carriers, Criteo S.A, and Adaptimmune Therapeutics Discovering Underlying Factors of Influence GlobeNewswire
Aug-15-18 07:30AM  Third Dosing Cohort to be initiated in MAGE-A4 SPEAR T-cell Basket Study After Favorable Review of Safety from One Billion Cell Dose Cohort GlobeNewswire
05:34AM  Edited Transcript of ADAP earnings conference call or presentation 2-Aug-18 12:00pm GMT Thomson Reuters StreetEvents
Aug-02-18 07:30AM  Adaptimmune Reports Second Quarter 2018 Financial Results and Business Update GlobeNewswire
06:00AM  Adaptimmune Therapeutics PLC Sponsored ADR to Host Earnings Call ACCESSWIRE
Jul-26-18 01:18PM  Adaptimmune to Report Second Quarter 2018 Financial Results and Business Update on Thursday August 2, 2018 GlobeNewswire
Jul-24-18 12:20PM  Why AdaptImmune collected $27.5M from GSK American City Business Journals
07:30AM  GSK and Adaptimmune Complete Transition of NY-ESO SPEAR T-cell Therapy Program to GSK GlobeNewswire
Jul-18-18 08:32AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:29AM  Adaptimmune Announces Favorable Review of Safety from One Billion Cell Dose Cohort in MAGE-A10 SPEAR T-cell Study and Initiation of Third Dosing Cohorts GlobeNewswire
Jun-27-18 10:52AM  Investors Are Undervaluing Adaptimmune Therapeutics plc (NASDAQ:ADAP) By 21.72% Simply Wall St.
Jun-11-18 07:30AM  Study published in Cancer Discovery Indicates that NY-ESO SPEAR T-cells are Long-lived, Selfrenewing, and Capable of Persistent Anti-Tumor Effects GlobeNewswire
Jun-07-18 07:45AM  Complimentary Technical Snapshots on Adverum Biotechnologies and Three More Biotech Stocks ACCESSWIRE
Jun-04-18 07:30AM  Adaptimmune Presents Detailed Safety Update from Ongoing MAGE-A10 Pilot Studies at ASCO GlobeNewswire
07:30AM  Adaptimmune Announces First Patient to Receive One Billion Target Cell Dose after Positive Safety Data from Pilot Study with MAGE-A4 SPEAR T-cells GlobeNewswire
Jun-02-18 08:00AM  Updated Myxoid/Round Cell Liposarcoma Data with NY-ESO, Presented at ASCO Annual Meeting, Further Supports Promising Benefit: Risk Profile GlobeNewswire
Jun-01-18 07:30AM  Investor Expectations to Drive Momentum within SK Telecom Co., Adaptimmune Therapeutics, Fiat Chrysler Automobiles N.V, Achillion Pharmaceuticals, Pzena Investment Management, and Sasol Discovering Underlying Factors of Influence GlobeNewswire
May-16-18 05:00PM  Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American Association for Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-15-18 06:59PM  Cramer's lightning round: Take a pass on Bristol-Myers Sq... CNBC Videos
06:47PM  Cramer's lightning round: Take a pass on Bristol-Myers Squibb shares for now CNBC
May-14-18 01:27PM  Edited Transcript of ADAP earnings conference call or presentation 9-May-18 12:00pm GMT Thomson Reuters StreetEvents
07:20AM  Wired News VBI Vaccines Reports Positive Data from Final Phase-1 Study for Preventative CMV Vaccine ACCESSWIRE
May-10-18 09:44AM  Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results Benzinga
May-09-18 07:30AM  Adaptimmune Reports First Quarter 2018 Financial Results and Business Update GlobeNewswire +7.01%
Apr-25-18 08:00AM  Adaptimmune to Report First Quarter 2018 Financial Results and Business Update on Wednesday May 9, 2018 GlobeNewswire
Apr-16-18 02:00PM  Adaptimmune Presents MAGE-A4 and MAGE-A10 pre-clinical data at American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire
Apr-12-18 08:00AM  Adaptimmune Announces Changes to Board of Directors GlobeNewswire +7.78%
Apr-09-18 07:30AM  Report: Exploring Fundamental Drivers Behind Brookfield Property Partners, Grupo Financiero Galicia S.A, Adaptimmune Therapeutics, Radware, Mimecast, and Bandwidth New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Apr-06-18 08:00AM  Adaptimmune to Present Two Posters at the Upcoming American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire
Mar-29-18 07:03AM  4 Strong Buy Biotech Stocks Poised to Explode TheStreet.com +7.26%
Mar-26-18 10:50AM  Adaptimmune Stock: How Long Will Rally Continue? Investopedia
Mar-21-18 11:19AM  GlaxoSmithKline prescribes commercial reboot for pharma division Reuters +10.04%
Mar-16-18 10:10AM  3 Hot Junior Biotech Plays Investopedia
Mar-15-18 09:30PM  Edited Transcript of ADAP earnings conference call or presentation 15-Mar-18 12:00pm GMT Thomson Reuters StreetEvents +18.78%
04:33PM  Why Noodles & Co., Blue Apron Holdings, and Adaptimmune Therapeutics Jumped Today Motley Fool
03:35PM  Here's What Lifted Adaptimmune Therapeutics plc Today Motley Fool
01:13PM  Adaptimmune Therapeutics shares soar 26% on news of positive early signs for cancer treatment MarketWatch
07:30AM  Adaptimmune Reports Fourth Quarter / Full Year 2017 Financial Results and Business Update GlobeNewswire
07:30AM  Adaptimmune Announces Responses in Second Solid Tumor Indication with NY-ESO SPEAR T-cells GlobeNewswire
06:00AM  Adaptimmune Therapeutics PLC Sponsored ADR to Host Earnings Call ACCESSWIRE
Mar-13-18 07:30AM  Investor Expectations to Drive Momentum within Methanex, YPF Sociedad Anonima, Adaptimmune Therapeutics, Horizon Pharma, Changyou, and China Yuchai International Discovering Underlying Factors of Influence GlobeNewswire
Mar-05-18 12:12PM  Adaptimmune to Report Fourth Quarter / Full Year 2017 Financial Results and Business Update on Thursday March 15, 2018 GlobeNewswire
Feb-12-18 03:26PM  Did Adaptimmune Therapeutics plcs (NASDAQ:ADAP) Recent Earnings Growth Beat The Trend? Simply Wall St.
Jan-08-18 08:00AM  Adaptimmune Announces Two Manufacturing Achievements on Its way to Become the First Fully Integrated TCR T-cell Therapy Company GlobeNewswire
08:00AM  Adaptimmune Announces Positive Safety Data from Pilot Studies with MAGE-A10 SPEAR T-cells and First Patient to Receive 1 billion Target Cell Dose GlobeNewswire
Jan-04-18 08:00AM  Paul Stead Joins Adaptimmune as Vice President of Business Development GlobeNewswire
Dec-05-17 05:00PM  Adaptimmune Data to be Presented at American Society of Hematology (ASH) Annual Meeting Confirm NY-ESO SPEAR T-cell Efficacy in Multiple Myeloma Pilot Study GlobeNewswire
Nov-14-17 07:40AM  Featured Company News - Adaptimmune Outlines Study Designs for Two T-Cell Clinical Trials - MAGE-A4 and NY-ESO SPEAR ACCESSWIRE
Nov-10-17 08:58AM  Adaptimmune Presents Study Designs for Ongoing MAGE-A4 and NY-ESO SPEAR T-cell Clinical Trials at the Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire
Nov-09-17 03:04PM  Valeant (VRX) Earnings and Revenues Beat in Q3, Stock Up Zacks
09:45AM  Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up Zacks
09:30AM  Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q3 Zacks
08:00AM  NY-ESO Data Presented at the Connective Tissue Oncology Society (CTOS) Annual Meeting Confirm Potential of Adaptimmunes SPEAR T-Cell Therapy GlobeNewswire
Nov-08-17 02:40PM  Adaptimmune Therapeutics Plc :ADAP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017 Capital Cube
11:56AM  Agenus (AGEN) Reports In Line Loss in Q3, Revenues Lag Zacks
Nov-07-17 09:39AM  What's in Store for Johnson Controls (JCI) in Q4 Earnings? Zacks
09:19AM  Endocyte (ECYT) Posts Narrower-than-Expected Q3 Loss Zacks
Nov-06-17 08:09AM  Adaptimmune marks Official Opening of U.K. Headquarters GlobeNewswire
Nov-03-17 02:22PM  Adaptimmune to Present Two Trials in Progress Posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire
02:17PM  Adaptimmune Data to be Presented in an Oral Presentation and a Trial in Progress Poster at the Connective Tissue Oncology Society (CTOS) Annual Meeting GlobeNewswire
Nov-02-17 01:56PM  Edited Transcript of ADAP earnings conference call or presentation 2-Nov-17 12:00pm GMT Thomson Reuters StreetEvents
01:12PM  Is Adaptimmune Therapeutics plc (ADAP) Undervalued? Simply Wall St.
11:55AM  Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q3 Zacks
07:30AM  Adaptimmune Reports Third Quarter 2017 Financial Results and Business Updates GlobeNewswire
06:10AM  Adaptimmune Therapeutics PLC Sponsored ADR to Host Earnings Call ACCESSWIRE
Nov-01-17 11:57AM  Dr. Reddy's (RDY) Q2 Earnings and Revenues Decline Y/Y Zacks
Oct-27-17 11:42AM  Seattle Genetics (SGEN) Loss Narrows in Q3, Revenues Beat Zacks +5.07%
11:11AM  Adaptimmune to Report Third Quarter 2017 Financial Results on November 2, 2017 GlobeNewswire
09:53AM  Alkermes (ALKS) Beats Q3 Earnings Estimates, Cuts Sales View Zacks
09:50AM  Bayer (BAYRY) Q3 Earnings Beat Estimates, Sales Down Y/Y Zacks
Oct-26-17 11:51AM  Vertex (VRTX) Beats on Q3 Earnings & Sales, Raises 2017 View Zacks
11:31AM  Sarepta (SRPT) Q3 Loss Narrows, Exondys 51 Sales View Raised Zacks
Oct-23-17 05:51PM  Sébastien Desprez Joins Adaptimmune as Vice President of Communications and Investor Relations GlobeNewswire
Oct-20-17 05:36PM  Abbvie Inks Immuno-Oncology Deal with Harpoon Therapeutics Zacks
Oct-18-17 10:17AM  Impax Laboratories and Amneal Pharmaceuticals Agree to Merge Zacks
Oct-17-17 10:04AM  Immune Design's Sarcoma Candidate to Enter Phase III in 2018 Zacks
08:57AM  The Zacks Analyst Blog Highlights: Bayer Aktiengesellschaft, Monsanto, Adaptimmune Therapeutics and Celgene Zacks
Oct-16-17 06:07PM  Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada Zacks
05:43PM  Bayer to Sell Select Business Lines to Close Monsanto Buyout Zacks
10:02AM  Shire's New Formulation of Oncaspar Gets CHMP Recommendation Zacks
Oct-13-17 11:05AM  AcelRx's Opioid Painkiller Dsuvia Gets CRL, Shares Plunge Zacks
Oct-09-17 10:15AM  Flexion's Zilretta Gets FDA Approval for Knee Pain, Stock Up Zacks
Sep-22-17 10:00AM  James Noble, Adaptimmune CEO, to Participate in Upcoming Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology GlobeNewswire -5.71%
Sep-21-17 08:35AM  Surging Earnings Estimates Signal Good News for Adaptimmune Therapeutics (ADAP) Zacks
Sep-13-17 10:33AM  Zacks.com featured highlights: Adaptimmune Therapeutics, Barnes Group, Mobile TeleSystems, JA Solar Holdings and Newtek Business Services Zacks
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients. It is developing MAGE A-10 peptide that is in Phase I/II clinical trials for the treatment of urothelial, melanoma, and head and neck cancers, as well as non-small cell lung cancer (NSCLC); MAGE-A4 to treat urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, and gastric cancers; and AFP SPEAR T-cell therapeutic candidate that is in Phase I/II clinical trials for targeting a peptide associated with hepatocellular carcinoma. Adaptimmune Therapeutics plc has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO SPEAR T-cell program; and strategic alliance with The University of Texas MD Anderson Cancer Center for the development of T-cell therapies for various cancers. The company also has a clinical trial collaboration agreement with Merck & Co., Inc. for the assessment of NY-ESO SPEAR T-cell therapy in combination with anti-programmed death-1 inhibitor in patients with multiple myeloma; and a research, collaboration, and license agreement with Universal Cells, Inc. to gene editing and HLA-engineering technology, as well as a co-development and co-commercialization agreement with Bellicum Pharmaceutical Inc. to evaluate, develop, and commercialize next generation T-cell therapies. Adaptimmune Therapeutics plc was founded in 2014 and is headquartered in Abingdon, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Binder-Scholl Gwendolyn KnowltChief Technology OfficerOct 01Sale13.7925,000344,7500Oct 02 07:58 PM
Viswanathan Ravi10% OwnerSep 07Buy1.6715,000,00025,000,50082,978,668Sep 10 04:49 PM
MOTT DAVID MDirectorSep 07Buy1.6715,000,00025,000,50082,978,668Sep 10 04:48 PM
SANDELL SCOTT D10% OwnerSep 07Buy1.6715,000,00025,000,50082,978,668Sep 10 04:49 PM
Sonsini Peter W.10% OwnerSep 07Buy1.6715,000,00025,000,50082,978,668Sep 10 04:49 PM
Florence Anthony A. Jr.10% OwnerSep 07Buy1.6715,000,00025,000,50082,978,668Sep 10 04:47 PM
KERINS PATRICK J10% OwnerSep 07Buy1.673,000,0005,000,10082,978,668Sep 10 04:48 PM
Behbahani AliDirectorSep 07Buy1.6712,000,00020,000,40012,000,000Sep 10 04:47 PM
BARRETT M JAMES10% OwnerSep 07Buy1.673,000,0005,000,10082,978,668Sep 10 04:45 PM
BARRIS PETER J10% OwnerSep 07Buy1.6715,000,00025,000,50082,978,668Sep 10 04:46 PM
BASKETT FOREST10% OwnerSep 07Buy1.6715,000,00025,000,50082,978,668Sep 10 04:46 PM
New Enterprise Associates 14, 10% OwnerSep 07Buy1.673,000,0005,000,10082,978,668Sep 10 04:45 PM
Binder-Scholl Gwendolyn KnowltChief Technology OfficerAug 29Sale10.2525,000256,2500Aug 31 08:02 PM
Thompson Peter A.DirectorJun 06Sale13.491,60021,5844,901,310Jun 06 06:16 PM
ORBIMED ADVISORS LLCDirectorJun 06Sale13.491,60021,5844,901,310Jun 06 06:10 PM
Thompson Peter A.DirectorJun 04Sale13.5717,100232,0474,902,910Jun 06 06:16 PM
ORBIMED ADVISORS LLCDirectorJun 04Sale13.5717,100232,0474,902,910Jun 06 06:10 PM
Thompson Peter A.DirectorJun 01Sale13.4950,000674,5004,920,010Jun 01 05:27 PM
ORBIMED ADVISORS LLCDirectorJun 01Sale13.4950,000674,5004,920,010Jun 01 05:25 PM
Thompson Peter A.DirectorMay 30Sale13.52121,0001,635,9204,970,010Jun 01 05:27 PM
ORBIMED ADVISORS LLCDirectorMay 30Sale13.52121,0001,635,9204,970,010Jun 01 05:25 PM
Thompson Peter A.DirectorMay 14Sale13.5010,300139,0505,091,010May 16 05:26 PM
ORBIMED ADVISORS LLCDirectorMay 14Sale13.5010,300139,0505,091,010May 16 05:22 PM
Thompson Peter A.DirectorMar 29Sale11.5331,983368,7645,101,310Mar 29 06:58 PM
ORBIMED ADVISORS LLCDirectorMar 29Sale11.5331,983368,7645,101,310Mar 29 06:54 PM
Viswanathan Ravi10% OwnerMar 27Buy1.926,000,00011,500,20079,978,672Mar 28 05:13 PM
MOTT DAVID MDirectorMar 27Buy1.926,000,00011,500,20079,978,672Mar 28 05:12 PM
SANDELL SCOTT D10% OwnerMar 27Buy1.926,000,00011,500,20079,978,672Mar 28 05:13 PM
Sonsini Peter W.10% OwnerMar 27Buy1.926,000,00011,500,20079,978,672Mar 28 05:13 PM
Florence Anthony A. Jr.10% OwnerMar 27Buy1.926,000,00011,500,20079,978,672Mar 28 05:11 PM
KERINS PATRICK J10% OwnerMar 27Buy1.926,000,00011,500,20079,978,672Mar 28 05:12 PM
BARRIS PETER J10% OwnerMar 27Buy1.926,000,00011,500,20079,978,672Mar 28 05:11 PM
BASKETT FOREST10% OwnerMar 27Buy1.926,000,00011,500,20079,978,672Mar 28 05:11 PM
New Enterprise Associates 14, 10% OwnerMar 27Buy1.926,000,00011,500,20079,978,672Mar 28 05:10 PM
BARRETT M JAMES10% OwnerMar 27Buy1.926,000,00011,500,20079,978,672Mar 28 05:10 PM
Thompson Peter A.DirectorMar 27Sale11.501,016,08411,684,9665,133,293Mar 29 06:58 PM
ORBIMED ADVISORS LLCDirectorMar 27Sale11.501,016,08411,684,9665,133,293Mar 29 06:54 PM
Viswanathan Ravi10% OwnerMar 26Buy1.90571,1641,087,55373,978,672Mar 28 05:13 PM
MOTT DAVID MDirectorMar 26Buy1.90571,1641,087,55373,978,672Mar 28 05:12 PM
SANDELL SCOTT D10% OwnerMar 26Buy1.90571,1641,087,55373,978,672Mar 28 05:13 PM
Sonsini Peter W.10% OwnerMar 26Buy1.90571,1641,087,55373,978,672Mar 28 05:13 PM
Florence Anthony A. Jr.10% OwnerMar 26Buy1.90571,1641,087,55373,978,672Mar 28 05:11 PM
KERINS PATRICK J10% OwnerMar 26Buy1.90571,1641,087,55373,978,672Mar 28 05:12 PM
BARRIS PETER J10% OwnerMar 26Buy1.90571,1641,087,55373,978,672Mar 28 05:11 PM
BASKETT FOREST10% OwnerMar 26Buy1.90571,1641,087,55373,978,672Mar 28 05:11 PM
New Enterprise Associates 14, 10% OwnerMar 26Buy1.90571,1641,087,55373,978,672Mar 28 05:10 PM
BARRETT M JAMES10% OwnerMar 26Buy1.90571,1641,087,55373,978,672Mar 28 05:10 PM
Sonsini Peter W.10% OwnerMar 23Buy1.95294,090572,35873,407,508Mar 23 06:33 PM
Viswanathan Ravi10% OwnerMar 23Buy1.95294,090572,35873,407,508Mar 23 06:34 PM
MOTT DAVID MDirectorMar 23Buy1.95294,090572,35873,407,508Mar 23 06:32 PM
SANDELL SCOTT D10% OwnerMar 23Buy1.95294,090572,35873,407,508Mar 23 06:33 PM
Florence Anthony A. Jr.10% OwnerMar 23Buy1.95294,090572,35873,407,508Mar 23 06:31 PM
KERINS PATRICK J10% OwnerMar 23Buy1.95294,090572,35873,407,508Mar 23 06:32 PM
BASKETT FOREST10% OwnerMar 23Buy1.95294,090572,35873,407,508Mar 23 06:31 PM
BARRETT M JAMES10% OwnerMar 23Buy1.95294,090572,35873,407,508Mar 23 06:29 PM
BARRIS PETER J10% OwnerMar 23Buy1.95294,090572,35873,407,508Mar 23 06:30 PM
New Enterprise Associates 14, 10% OwnerMar 23Buy1.95294,090572,35873,407,508Mar 23 06:29 PM
Sonsini Peter W.10% OwnerMar 22Buy1.90869,5741,655,66973,113,418Mar 23 06:33 PM
Viswanathan Ravi10% OwnerMar 22Buy1.90869,5741,655,66973,113,418Mar 23 06:34 PM
MOTT DAVID MDirectorMar 22Buy1.90869,5741,655,66973,113,418Mar 23 06:32 PM
SANDELL SCOTT D10% OwnerMar 22Buy1.90869,5741,655,66973,113,418Mar 23 06:33 PM
Florence Anthony A. Jr.10% OwnerMar 22Buy1.90869,5741,655,66973,113,418Mar 23 06:31 PM
KERINS PATRICK J10% OwnerMar 22Buy1.90869,5741,655,66973,113,418Mar 23 06:32 PM
BASKETT FOREST10% OwnerMar 22Buy1.90869,5741,655,66973,113,418Mar 23 06:31 PM
BARRETT M JAMES10% OwnerMar 22Buy1.90869,5741,655,66973,113,418Mar 23 06:29 PM
BARRIS PETER J10% OwnerMar 22Buy1.90869,5741,655,66973,113,418Mar 23 06:30 PM
New Enterprise Associates 14, 10% OwnerMar 22Buy1.90869,5741,655,66973,113,418Mar 23 06:29 PM
Sonsini Peter W.10% OwnerMar 21Buy1.81104,844189,82072,243,844Mar 23 06:33 PM
Viswanathan Ravi10% OwnerMar 21Buy1.81104,844189,82072,243,844Mar 23 06:34 PM
MOTT DAVID MDirectorMar 21Buy1.81104,844189,82072,243,844Mar 23 06:32 PM
SANDELL SCOTT D10% OwnerMar 21Buy1.81104,844189,82072,243,844Mar 23 06:33 PM
Florence Anthony A. Jr.10% OwnerMar 21Buy1.81104,844189,82072,243,844Mar 23 06:31 PM
KERINS PATRICK J10% OwnerMar 21Buy1.81104,844189,82072,243,844Mar 23 06:32 PM
BASKETT FOREST10% OwnerMar 21Buy1.81104,844189,82072,243,844Mar 23 06:31 PM
BARRETT M JAMES10% OwnerMar 21Buy1.81104,844189,82072,243,844Mar 23 06:29 PM
BARRIS PETER J10% OwnerMar 21Buy1.81104,844189,82072,243,844Mar 23 06:30 PM
New Enterprise Associates 14, 10% OwnerMar 21Buy1.81104,844189,82072,243,844Mar 23 06:29 PM
Rawcliffe AdrianChief Financial OfficerMar 20Sale1.71600,0001,026,0000Mar 22 09:01 PM